Ticlon2mg

Ticlon is a non-benzodiazepine sedative-hypnotic (a "Z-drug") indicated for:

• Treatment of insomnia (FDA-approved, established use) — shown to reduce sleep latency (time to fall asleep) and to improve sleep maintenance (reduce wake time after sleep onset), for both sleep-onset and sleep-maintenance difficulties. Unlike some other hypnotics, Ticlon does not carry a labeled restriction limiting duration of use, but it is generally intended for the shortest effective duration with periodic reassessment.

Ticlon is not approved for use in pediatric patients; studies in adolescents did not demonstrate efficacy (see Use in Special Populations).

Each tablet contains Eszopiclone as the active pharmaceutical ingredient, commonly available in strengths of 1 mg, 2 mg, and 3 mg for oral administration. Tablets also contain standard pharmaceutical excipients (e.g., lactose, microcrystalline cellulose, colorants) that vary by manufacturer/brand.

Ticlon is a non-benzodiazepine hypnotic agent belonging to the cyclopyrrolone class. Although structurally unrelated to benzodiazepines, Ticlon acts at the same benzodiazepine binding site on the GABA-A receptor complex, producing sedative effects used for the short- to longer-term management of insomnia.

It is taken orally, immediately before bedtime, and is absorbed rapidly, making it effective for both difficulty falling asleep and difficulty staying asleep.

Ticlon belongs to the non-benzodiazepine sedative-hypnotic class (cyclopyrrolone derivative, commonly grouped with the "Z-drugs" such as zolpidem and zaleplon). It is classified as a Schedule IV controlled substance due to its potential for dependence and abuse.

Eszopiclone is a cyclopyrrolone derivative that, although chemically distinct from benzodiazepines, binds to the benzodiazepine recognition site on the GABA-A receptor-chloride ion channel complex, particularly at receptor subtypes near or overlapping the benzodiazepine binding domain. This binding enhances the inhibitory effects of GABA (gamma-aminobutyric acid), the principal inhibitory neurotransmitter in the central nervous system, resulting in sedative, hypnotic, and central nervous system depressant effects.

Pharmacokinetics: Eszopiclone is rapidly absorbed after oral administration, with peak plasma concentrations reached within about 1 hour. It undergoes extensive hepatic metabolism, primarily via CYP3A4 and CYP2E1, and has an elimination half-life of approximately 6 hours (may be prolonged in the elderly and in hepatic impairment). It is eliminated mainly via the kidneys as inactive metabolites.

Ticlon should be swallowed whole with a glass of water, taken right before getting into bed, and only when a full night's sleep (7-8 hours) is planned. Do not take a dose while still up and active, and avoid taking with or right after a high-fat/heavy meal, as this may delay the onset of effect.

• Opioids and other CNS depressants (including alcohol, benzodiazepines, sedatives, and certain antidepressants/antipsychotics): Concomitant use with Ticlon produces additive central nervous system depression, and may result in profound sedation, respiratory depression, coma, and death. Concomitant use with opioids should be reserved for patients in whom alternative treatment options are inadequate, using the lowest effective doses for the shortest duration, with close monitoring.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir): May significantly increase Ticlon plasma concentrations, increasing sedative/CNS depressant effects; dose reduction of Ticlon is recommended (do not exceed 2 mg).
• CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's Wort): May reduce Ticlon plasma concentrations and reduce its efficacy.
• Olanzapine and other centrally-acting sedating agents: May cause additive psychomotor impairment beyond that seen with either agent alone.

The most common side effect of Ticlon is an unpleasant (metallic/bitter) taste, reported in a substantial proportion of patients, particularly at higher doses. Other side effects include:

• Drowsiness and next-day somnolence
• Dizziness
• Dry mouth
• Headache
• Mild anxiety
• Rash
• Hallucinations (uncommon)

Serious risks (see Precautions and Warnings for full detail): complex sleep behaviors (e.g., sleep-walking, sleep-driving, preparing and eating food, or making phone calls while not fully awake, with amnesia for the event), next-day impairment of driving/mental alertness, and dependence/withdrawal symptoms with abrupt discontinuation after prolonged use.

Pregnancy: Data on the use of Ticlon in pregnant women are limited. Use during pregnancy only if the potential benefit clearly justifies the potential risk to the fetus, and only under the guidance of a physician. Neonates whose mothers received sedative-hypnotics like Ticlon late in pregnancy may exhibit sedation and/or withdrawal symptoms.

Lactation: Ticlon and its metabolites are excreted in human breast milk. Because of the potential for sedation and other adverse effects in a nursing infant, a decision should be made whether to discontinue breastfeeding or discontinue Ticlon, taking into account the importance of the drug to the mother; consult a physician before use while breastfeeding.

Boxed Warning: Complex Sleep Behaviors

Serious injuries and deaths have occurred as a result of complex sleep behaviors that have occurred after taking Ticlon, including sleep-walking, sleep-driving, and engaging in other activities while not fully awake (such as preparing and eating food, making phone calls, or having sex), with amnesia for the event. These behaviors have occurred in patients with and without prior history of such behaviors, even at the lowest recommended doses, and can occur after a single dose. Ticlon should be discontinued immediately if a complex sleep behavior occurs.

CNS Depression and Next-Day Impairment

Ticlon causes CNS depression and can impair alertness, motor coordination, and driving ability the day following use, even in the absence of subjective awareness of impairment. Patients must allow a full 7-8 hours for sleep before engaging in activities requiring complete mental alertness (e.g., driving).

Alcohol and Other CNS Depressants

Do not combine Ticlon with alcohol or other CNS depressants/opioids due to risk of profound sedation and respiratory depression (see Interactions).

Abnormal Thinking, Behavioral Changes, and Psychiatric Effects

Worsening of depression, suicidal thoughts, agnitation, hallucinations, and other abnormal behavioral changes have been reported; use with caution in patients with depression or a history of substance abuse, and monitor closely.

Dependence, Abuse, and Withdrawal

Ticlon is a Schedule IV controlled substance with potential for dependence and abuse, particularly with prolonged use or in patients with a history of substance use disorder. Abrupt discontinuation after prolonged use may cause withdrawal symptoms (e.g., anxiety, abnormal dreams, nausea, rarely seizures); dose should be tapered under physician guidance.

Respiratory Depression

Use with caution in patients with compromised respiratory function (e.g., COPD, sleep apnea), as Ticlon may worsen respiratory drive.

Elderly Patients

Use lower doses in elderly patients due to increased sensitivity to CNS effects and increased risk of falls, confusion, and cognitive impairment.

Duration of Use

Ticlon is generally intended for short-term or intermittent use; periodic reassessment is recommended for prolonged use, and the lowest effective dose should always be used.

Overdose of Ticlon may cause excessive sedation, confusion, impaired coordination, respiratory depression, coma, and, in severe cases, death — particularly if taken together with alcohol or other CNS depressants. There is no specific antidote confirmed safe and effective for Ticlon overdose. In case of suspected overdose, seek immediate medical attention or contact emergency services/poison control. Management is generally supportive and symptomatic (e.g., airway protection, monitoring of vital signs and respiratory status, gastric decontamination if appropriate and performed promptly by medical personnel). Flumazenil may be considered by a physician in select cases but carries its own risks (e.g., seizures) and should only be used under close medical supervision.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric Use

Safety and efficacy of Ticlon in pediatric patients have not been established. A controlled trial in adolescent patients (12 to 17 years) with insomnia associated with ADHD did not demonstrate efficacy, and adverse events including hallucinations and other psychiatric symptoms were reported; Ticlon is not recommended for use in this population.

Elderly (Geriatric) Use

Elderly patients are more sensitive to the sedative and psychomotor effects of Ticlon. Lower starting doses (1 mg, maximum 2 mg) are recommended, with careful monitoring for excessive sedation, dizziness, confusion, and falls (see Dosage and Administration).

Hepatic Impairment

Clearance of Ticlon is reduced in patients with hepatic impairment; a lower starting dose (1 mg) and maximum dose (2 mg) are recommended.

Renal Impairment

No dosage adjustment is generally required in mild to moderate renal impairment; data in severe renal impairment are limited, so use with caution.

Respiratory Disease

Use with caution in patients with compromised respiratory function due to risk of respiratory depression (see Precautions).

Ticlon is generally used for the shortest duration needed to manage insomnia. While its label does not impose a strict maximum duration (unlike some other hypnotics), continued use beyond 7-10 days should prompt reevaluation of the underlying cause of insomnia, and long-term use should be periodically reassessed by a physician given the risks of dependence, tolerance, and withdrawal.

Eszopiclone is a non-benzodiazepine sedative-hypnotic (cyclopyrrolone class / "Z-drug").

Eszopiclone binds to the benzodiazepine recognition site of the GABA-A receptor-chloride channel complex in the central nervous system, potentiating the inhibitory effects of GABA and producing sedative-hypnotic effects that promote sleep onset and maintenance.

C

Ticlon is not approved for use in pediatric patients. A clinical trial in adolescents (12-17 years) failed to demonstrate efficacy, and psychiatric adverse effects (including hallucinations) were observed; therefore, Ticlon is not recommended for children or adolescents.